Primigyn Special Precautions

Primigyn should be administered by experienced healthcare providers and in hospital settings with appropriate obstetrical care facilities. Placement of Primigyn should be endocervical, just below the level of the internal orifice of the uterus (internal os) and not in the extra-amniotic space to avoid uterine hyperstimulation. Uterine activity, fetal status, cervical dilatation and effacement should be carefully monitored for early identification of any undesirable effects, such as hypertonic myometrial contractions and fetal distress. Use with caution in patients with acute pelvic inflammatory disease, ruptured membranes, asthma, glaucoma, cardiac disease, renal or hepatic impairment and pulmonary disease. Since prostaglandins augment the action of oxytocin on the gravid uterus, the uterine activity should be carefully monitored when oxytocin is use d subsequent to Primigyn for labor induction.
The risk of uterine rupture should be considered if hypertonic myometrial contractions develop after Primigyn placement.
There is increased risk of post-partum disseminated intravascular coagulation in women aged 30 years or older, those with complications during pregnancy and those with a gestational age over 40 weeks.
Primigyn placement may result in inadvertent disruption and subsequent embolization of antigenic tissue. It rarely causes the development of the anaphylactoid syndrome of pregnancy